{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T15:51:27Z","timestamp":1789314687459,"version":"build-2803163510"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Genomic alterations (GA) in NF2 tumor-suppressor gene have been associated with aggressive behavior in kidney tumors. We used comprehensive genomic profiling (CGP) to evaluate the frequencies of NF2 GA in histologic subtypes of kidney tumors and co-occurring GA in other genes and biomarkers. Advanced kidney tumors included 1875 clear cell (ccRCC), 405 papillary (pRCC), 108 chromophobe (chRCC), 171 sarcomatoid (sRCC), 61 collecting duct (cdRCC), 49 medullary (mRCC), 134 unclassified (uRCC), 906 urothelial carcinoma of renal pelvis (UC), and 147 Wilms tumors underwent hybrid-capture based CGP to evaluate all classes of GA. 192 (4.9%) of kidney tumors featured NF2 GA which were predominantly structural variant mutations (89%), followed by copy number alterations (9%). Gender and age were similar between NF2-mutant (NF2mut) and NF2-wild type (NF2wt) cohorts with male preponderance. NF2 GA frequency was highest in cdRCC (30%), sRCC (21%), uRCC (15%), and pRCC (12%) while lowest in ccRCC (3%), UC (3%) Wilms tumor (1%), and chRCC (0%). NF2 mutational status was associated with loss of Ch 22 (P &amp;lt; .001). NF2mut RCC harbored co-occurring GA including CDKN2A, CDKN2B, SETD2, and BAP1. VHL, PBRM1, PTEN, and FGFR3 GA were significantly more frequent in NF2wt than in NF2mut tumors. MTOR pathway GAs were uncommon in NF2mut tumors. No NF2 mutated RCC featured MSI-high or high TMB. sRCC was associated with high PD-L1 expression. PD-L1 SP142 tumoral (P = .04) and immune cells (P = .013) were more frequent in NF2mut as compared to NF2wt group. Among histologic subtypes of RCC, cdRCC, sRCC, pRCC, and uRCC are enriched in NF2 GA. Co-occurrent GA in CDKN2A\/B, SETD2, and BAP1 may represent potential therapeutic targets. Higher level of PD-L1 expression in NF2mut cohort suggests that these tumors might be sensitive to immune checkpoint inhibitor therapies.<\/jats:p>","DOI":"10.1093\/oncolo\/oyad040","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T14:35:41Z","timestamp":1678804541000},"page":"e508-e519","source":"Crossref","is-referenced-by-count":18,"title":["Comprehensive Genomic Profiling of <i>NF2<\/i>-Mutated Kidney Tumors Reveals Potential Targets for Therapy"],"prefix":"10.1093","volume":"28","author":[{"given":"Sean M","family":"Hacking","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Rhode Island Hospital, Warren Alpert Medical School of Brown University , Providence, RI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Pavlick","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc. , Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Rhode Island Hospital, Warren Alpert Medical School of Brown University , Providence, RI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedito A","family":"Carneiro","sequence":"additional","affiliation":[{"name":"Lifespan Cancer Institute, Legorreta Cancer Center at Brown University , Providence, RI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Mullally","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Rhode Island Hospital, Warren Alpert Medical School of Brown University , Providence, RI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaolei","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Rhode Island Hospital, Warren Alpert Medical School of Brown University , Providence, RI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Canepa","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Rhode Island Hospital, Warren Alpert Medical School of Brown University , Providence, RI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennady","family":"Bratslavsky","sequence":"additional","affiliation":[{"name":"Department of Urology, State University of New York (SUNY), Upstate Medical University , Syracuse, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jacob","sequence":"additional","affiliation":[{"name":"Department of Urology, State University of New York (SUNY), Upstate Medical University , Syracuse, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-2756","authenticated-orcid":false,"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[{"name":"Department of GU Medical Oncology, San Raffaele University , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5723-1972","authenticated-orcid":false,"given":"Philippe E","family":"Spiess","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, Moffitt Cancer Center , Tampa, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Rhode Island Hospital, Warren Alpert Medical School of Brown University , Providence, RI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Yakirevich","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Rhode Island Hospital, Warren Alpert Medical School of Brown University , Providence, RI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Ross","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc. , Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,14]]},"reference":[{"key":"2023070520022679500_CIT0001","volume-title":"WHO Classification of Tumours of the Urinary System and Male Genital Organs","author":"Moch","year":"2016","edition":"4"},{"issue":"12","key":"2023070520022679500_CIT0002","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41585-020-00382-9","article-title":"Sarcomatoid renal cell carcinoma: biology, natural history and management","volume":"17","author":"Blum","year":"2020","journal-title":"Nat Rev Urol."},{"issue":"10","key":"2023070520022679500_CIT0003","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.urolonc.2018.10.027","article-title":"Mutations in renal cell carcinoma","volume":"38","author":"D\u2019Avella","year":"2020","journal-title":"Urol Oncol."},{"issue":"5","key":"2023070520022679500_CIT0004","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nrc1364","article-title":"Searching for the hereditary causes of renal-cell carcinoma","volume":"4","author":"Pavlovich","year":"2004","journal-title":"Nat Rev Cancer."},{"issue":"4","key":"2023070520022679500_CIT0005","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/his.14700","article-title":"WHO 2022 landscape of papillary and chromophobe renal cell carcinoma","volume":"81","author":"Lobo","year":"2022","journal-title":"Histopathology."},{"issue":"5","key":"2023070520022679500_CIT0006","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/PAS.0000000000001846","article-title":"NF2-mutated renal carcinomas have common morphologic features which overlap with biphasic hyalinizing psammomatous renal cell carcinoma: a comprehensive study of 14 cases","volume":"46","author":"Paintal","year":"2022","journal-title":"Am J Surg Pathol."},{"issue":"7","key":"2023070520022679500_CIT0007","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/PAS.0000000000001467","article-title":"Biphasic hyalinizing psammomatous renal cell carcinoma (BHP RCC): a distinctive neoplasm associated with somatic NF2 mutations","volume":"44","author":"Argani","year":"2020","journal-title":"Am J Surg Pathol."},{"issue":"21","key":"2023070520022679500_CIT0008","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.21.01944","article-title":"Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates","volume":"40","author":"Lee","year":"2022","journal-title":"J Clin Oncol."},{"issue":"1","key":"2023070520022679500_CIT0009","first-page":"1","article-title":"Neurofibromatosis type 2 protein, NF2: an uncoventional cell cycle regulator","volume":"33","author":"Beltrami","year":"2013","journal-title":"Anticancer Res."},{"issue":"5","key":"2023070520022679500_CIT0010","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2015.125","article-title":"Role of Merlin\/NF2 inactivation in tumor biology","volume":"35","author":"Petrilli","year":"2016","journal-title":"Oncogene."},{"key":"2023070520022679500_CIT0011","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-4-16","article-title":"Neurofibromatosis type 2 (NF2): a clinical and molecular review","volume":"4","author":"Evans","year":"2009","journal-title":"Orphanet J Rare Dis."},{"issue":"7","key":"2023070520022679500_CIT0012","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.cub.2006.02.063","article-title":"The tumor suppressors Merlin and expanded function cooperatively to modulate receptor endocytosis and signaling","volume":"16","author":"Maitra","year":"2006","journal-title":"Curr Biol."},{"issue":"6","key":"2023070520022679500_CIT0013","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/nrn1407","article-title":"Merlin and the ERM proteins in Schwann cells, neurons and growth cones","volume":"5","author":"Ramesh","year":"2004","journal-title":"Nat Rev Neurosci."},{"issue":"6","key":"2023070520022679500_CIT0014","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/1756287215597647","article-title":"Targeting PD-1\/PD-L1 in the treatment of metastatic renal cell carcinoma","volume":"7","author":"Weinstock","year":"2015","journal-title":"Ther Adv Urol"},{"issue":"9","key":"2023070520022679500_CIT0015","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1158\/1078-0432.CCR-19-3323","article-title":"Targeting PD-1 or PD-L1 in metastatic kidney cancer: combination therapy in the first-line setting","volume":"26","author":"Aggen","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2023070520022679500_CIT0016","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J ImmunoTher Cancer."},{"issue":"7","key":"2023070520022679500_CIT0017","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-05-4303","article-title":"Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up","volume":"66","author":"Thompson","year":"2006","journal-title":"Cancer Res."},{"issue":"19","key":"2023070520022679500_CIT0018","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med."},{"issue":"14","key":"2023070520022679500_CIT0019","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med."},{"issue":"12","key":"2023070520022679500_CIT0020","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med."},{"issue":"12","key":"2023070520022679500_CIT0021","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med."},{"issue":"11","key":"2023070520022679500_CIT0022","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol."},{"issue":"1","key":"2023070520022679500_CIT0023","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"issue":"6","key":"2023070520022679500_CIT0024","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jmoldx.2019.06.011","article-title":"A novel next-generation sequencing approach to detecting microsatellite instability and pan-tumor characterization of 1000 microsatellite instability-high cases in 67,000 patient samples","volume":"21","author":"Trabucco","year":"2019","journal-title":"J Mol Diagn."},{"issue":"6","key":"2023070520022679500_CIT0025","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/WCO.0000000000000615","article-title":"New molecular targets in meningiomas: the present and the future","volume":"31","author":"Venur","year":"2018","journal-title":"Curr Opin Neurol."},{"issue":"6","key":"2023070520022679500_CIT0026","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/1878-0261.12651","article-title":"Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival","volume":"14","author":"Quetel","year":"2020","journal-title":"Mol Oncol."},{"issue":"3","key":"2023070520022679500_CIT0027","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.eururo.2015.06.019","article-title":"Characterization of clinical cases of collecting duct carcinoma of the kidney assessed by comprehensive genomic profiling","volume":"70","author":"Pal","year":"2016","journal-title":"Eur Urol."},{"issue":"1","key":"2023070520022679500_CIT0028","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.eururo.2017.05.033","article-title":"Characterization of clinical cases of advanced papillary renal cell carcinoma via comprehensive genomic profiling","volume":"73","author":"Pal","year":"2018","journal-title":"Eur Urol."},{"issue":"6_suppl","key":"2023070520022679500_CIT0029","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1200\/JCO.2020.38.6_suppl.726","article-title":"NF2 mutation-driven renal cell carcinomas (RCC): A comprehensive genomic profiling (CGP) study","volume":"38","author":"Yakirevich","year":"2020","journal-title":"J Clin Oncol."},{"issue":"2","key":"2023070520022679500_CIT0030","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.eururo.2016.01.051","article-title":"Genomic characterization of renal cell carcinoma with sarcomatoid dedifferentiation pinpoints recurrent genomic alterations","volume":"70","author":"Malouf","year":"2016","journal-title":"Eur Urol."},{"key":"2023070520022679500_CIT0031","doi-asserted-by":"crossref","first-page":"13131","DOI":"10.1038\/ncomms13131","article-title":"Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets","volume":"7","author":"Chen","year":"2016","journal-title":"Nat Commun."},{"issue":"11","key":"2023070520022679500_CIT0032","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/2159-8290.CD-16-0267","article-title":"Biallelic alteration and dysregulation of the hippo pathway in mucinous tubular and spindle cell carcinoma of the kidney","volume":"6","author":"Mehra","year":"2016","journal-title":"Cancer Discov"},{"issue":"3","key":"2023070520022679500_CIT0033","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2016.10.007","article-title":"Genomic biomarkers of a randomized trial comparing first-line everolimus and sunitinib in patients with metastatic renal cell carcinoma","volume":"71","author":"Hsieh","year":"2017","journal-title":"Eur Urol."},{"issue":"8","key":"2023070520022679500_CIT0034","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/s13059-014-0433-z","article-title":"Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution","volume":"15","author":"Fisher","year":"2014","journal-title":"Genome Biol."},{"issue":"1","key":"2023070520022679500_CIT0035","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41598-020-57534-5","article-title":"Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers","volume":"10","author":"Malouf","year":"2020","journal-title":"Sci Rep."},{"issue":"16","key":"2023070520022679500_CIT0036","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1158\/0008-5472.CAN-18-4093","article-title":"Inactivation of Bap1 cooperates with losses of Nf2 and Cdkn2a to drive the development of pleural malignant mesothelioma in conditional mouse models","volume":"79","author":"Kukuyan","year":"2019","journal-title":"Cancer Res."},{"issue":"1","key":"2023070520022679500_CIT0037","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s40478-020-01040-2","article-title":"Distinct genomic subclasses of high-grade\/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic","volume":"8","author":"Williams","year":"2020","journal-title":"Acta Neuropathol Commun."},{"issue":"3","key":"2023070520022679500_CIT0038","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/j.ijrobp.2015.07.444","article-title":"A comprehensive genome-based mutational analysis by next generation sequencing technology in patients with malignant pleural and peritoneal mesothelioma.","volume":"93","author":"Ugurluer","year":"2015","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"1","key":"2023070520022679500_CIT0039","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3390\/curroncol29010017","article-title":"Intraventricular meningiomas: clinical-pathological and genetic features of a monocentric series","volume":"29","author":"Ammendola","year":"2022","journal-title":"Curr Oncol"},{"issue":"6","key":"2023070520022679500_CIT0040","doi-asserted-by":"crossref","first-page":"e20191257","DOI":"10.1084\/jem.20191257","article-title":"Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice","volume":"217","author":"Badhai","year":"2020","journal-title":"J Exp Med."},{"issue":"237","key":"2023070520022679500_CIT0041","doi-asserted-by":"crossref","first-page":"237ra268","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci Transl Med."},{"issue":"5","key":"2023070520022679500_CIT0042","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1158\/1078-0432.CCR-12-1904","article-title":"mTORC1 inhibitors suppress meningioma growth in mouse models","volume":"19","author":"Pachow","year":"2013","journal-title":"Clin Cancer Res."},{"issue":"2","key":"2023070520022679500_CIT0043","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/MAO.0b013e31823e287f","article-title":"Treatment of vestibular schwannoma cells with ErbB inhibitors","volume":"33","author":"Bush","year":"2012","journal-title":"Otol Neurotol."},{"issue":"4","key":"2023070520022679500_CIT0044","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/neuonc\/noz002","article-title":"Preclinical assessment of MEK1\/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development","volume":"21","author":"Fuse","year":"2019","journal-title":"Neuro Oncol"},{"issue":"1","key":"2023070520022679500_CIT0045","doi-asserted-by":"crossref","first-page":"5679","DOI":"10.1038\/s41467-020-19342-3","article-title":"Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing","volume":"11","author":"Lang","year":"2020","journal-title":"Nat Commun."},{"issue":"12","key":"2023070520022679500_CIT0046","doi-asserted-by":"crossref","first-page":"10723","DOI":"10.18632\/oncotarget.24112","article-title":"Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers","volume":"9","author":"Sourbier","year":"2018","journal-title":"Oncotarget"},{"issue":"9","key":"2023070520022679500_CIT0047","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.20.02363","article-title":"Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"J Clin Oncol."},{"issue":"12","key":"2023070520022679500_CIT0048","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol."},{"issue":"9","key":"2023070520022679500_CIT0049","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med."},{"issue":"2","key":"2023070520022679500_CIT0050","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41379-019-0309-6","article-title":"Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma","volume":"33","author":"Kinoshita","year":"2020","journal-title":"Mod Pathol."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/7\/e508\/50826017\/oyad040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/7\/e508\/50826017\/oyad040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T20:03:32Z","timestamp":1688587412000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/7\/e508\/7077239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":50,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,3,14]]},"published-print":{"date-parts":[[2023,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad040","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2023,3,14]]}}}